Drug Trial Radar · NCT05607563
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
54
Planned (sponsor's estimate)
Start
Nov 21, 2022
Primary completion
Nov 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Biotheus Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose(RP2D) of PM1009. PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.
Conditions
- Advanced Tumor
Interventions
PM1009 injectionDrug
Participants receive PM1009 intravenously, every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limited Toxicity(DLT)Time frame: up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Orient Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.